Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain?

European Journal of Pharmacology

Volumn 455, Issue 1, 2002, Pages 1-18

  Westerink, Ben H C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antipsychotic drug; Clozapine; Dopamine; Mesolimbic; Prefrontal cortex

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; 2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; AMPEROZIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERLAPINE; RACLOPRIDE; REMOXIPRIDE; RITANSERIN; SEROTONIN 2 ANTAGONIST; SERTINDOLE; SULPIRIDE; TEFLUDAZINE; THIORIDAZINE; UNCLASSIFIED DRUG;

AKATHISIA; BASAL GANGLION; COGNITIVE DEFECT; DEPOLARIZATION; DISSOCIATION CONSTANT; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; EXTRAPYRAMIDAL SYMPTOM; FRONTAL CORTEX; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0037159603     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02496-2     Document Type: Article

References (192)

1. Aghajanian G.K., Bunney B.S. Central dopaminergic neurons: neurophysiological identification and responses to drugs. Frontiers in Catecholamine Research Research. 1973;643-648 Pergamon, Great Britain.
2. Andén N.-E. Dopamine turnover in the corpus striatum and the limbic system after treatment with neuroleptic and anti-acetylcholine drugs. J. Pharm. Pharmacol. 24:1972;905-906.
3. Andén N.-E., Stock G. Effect of clozapine on the turnover of dopamine in the corpus striatum and in the limbic system. J. Pharm. Pharmacol. 25:1973;346-348.
4. Andén N.E., Roos B.E., Werdinius B. Effects of chlorpromazine, haloperidol and resrpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci. 3:1964;149-158.
5. Andén N.-E., Corrodi H., Fuxe K., Ungerstedt U. Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. Eur. J. Pharmacol. 15:1971;193-199.
6. Andén N.-E., Corrodi H., Fuxe K. Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine-beta-hydroxylase inhibitors. J. Pharm. Pharmacol. 24:1972;177-182.
7. Andersson J.L., Marcus M., Nomikos G.G., Svensson T.H. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmacol. 349:1994;236-243.
8. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathe J.M., Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;374-385.
9. Angst J., Bente D., Berner P., Heimann H., Helmchen H., Hippius H. Das klinische Wirkungsbild von Clozapin. Pharmakopsychiatrie. 4:1971;192-200.
10. Bacopoulos N.G. Biochemical mechanism of tolerance to neuroleptic drugs; regional differences in rat brain. Eur. J. Pharmacol. 70:1981;585-586.
11. Bannet J., Gillis S., Ebstein R.P., Belmaker R.H. Effect of chronic sulpiride on striatal spiperone binding. Int. Pharmacopsychiatry. 15:1980;334-337.
12. Bartholini G. Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system. J. Pharm. Pharmacol. 28:1976;429-433.
13. Bartholini G., Haefely W., Jalfre M., Keller H.H., Pletscher A. Effects of clozapine on cerebral catecholaminergic neurone systems. Br. J. Pharmacol. 46:1972;736-740.
14. Bowers M.B. Homovanillic acid in caudate and prefrontal cortex following neuroleptics. Eur. J. Pharmacol. 99:1984;103-105.
15. Bowers M.G., Rozitis A. Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J. Pharm. Pharmacol. 26:1974;743-745.
16. Bowers M.B., Rozitis A. Brain homovanillic acid: regional changes over time with antipsychotic drugs. Eur. J. Pharmacol. 39:1976;109-115.
17. Bunney B.S., Grace A.A. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci. 23:1978;1715-1727.
18. Bunney B.S., Walters J.R., Roth R.H., Aghajanian G.K. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity. J. Pharmacol. Exp. Ther. 185:1973;560-571.
19. Burki H.R. Effects of fluperlapine on dopaminergic systems in the brain. Psychopharmacology. 89:1986;77-84.
20. Burki H.R., Ruch W., Asper H., Baggiolini M., Stille G. Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur. J. Pharmacol. 27:1974;180-190.
21. Burki H.R., Ruch W., Asper H. Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacol. 41:1975;27-33.
22. Burt D.R., Enna S.J., Creese I., Snyder S.H. Dopamine receptor binding in the corpus striatum of mammalian brain. Proc. Natl. Acad. Sci. U. S. A. 72:1975;4655-4659.
23. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 196:1977;326-328.
24. Carboni E., Rolando M.T., Silvagni A., Di Chiara G. Increase of dialysate dopamine in the bed nucleus of stria terminalis by clozapine and related neuroleptics. Neuropsychopharmacology. 22:2000;140-147.
25. Carlsson A., Lindqvist M. Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharm. Toxicol. 20:1963;140-144.
26. Chang W.H., Chen T.Y., Wu H.S., Hu W.H., Yeh E.K. Dose-response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies. Psychopharmacology. 95:1988;459-462.
27. Chiodo L.A., Bunney B.S. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J. Neurosci. 3:1983;1607-1619.
28. Chiodo L.A., Bunney B.S. Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 5:1985;2539-2544.
29. Chiodo L.A., Bannon M.J., Grace A.A., Roth R.H., Bunney B.S. Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience. 12:1984;1-16.
30. Chivers J.K., Reavill C., Jenner P., Marsden C.D. Definition of the in-vivo binding of [3H]spiperone in rat brain using substituted benzamide drugs. J. Pharm. Pharmacol. 41:1989;106-111.
31. Clark D., Chiodo L.A. Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat. Synapse. 2:1988;474-485.
32. Cox R.F., Waszczak B.L. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis. Brain Res. 534:1990;273-282.
33. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 192:1976;481-483.
34. Crow T.J., Johnstone E.C., Deakin J.F., Longden A. Dopamine and schizophrenia. Lancet. 2:1976;563-566.
35. Crow T.J., Deakin J.F., Longden A. The nucleus accumbens: a possible site of antipsychotic action of neuroleptic drugs? Psychol. Med. 7:1977;213-221.
36. Da Prada M., Pletscher A. On the mechanism of chlorpromazine-induced changes of cerebral homovanillic acid levels. J. Pharm. Pharmacol. 18:1966;628-630.
37. Di Chiara G., Porceddu M.L., Fratta W., Gessa G.L. Postsynaptic receptors are not essential for dopaminergic feedback regulation. Nature. 267:1977;270-272.
38. Di Giovanni G., Di Mascio M., Di Matteo V., Esposito E. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons. J. Pharmacol. Exp. Ther. 287:1998;51-57.
39. Dresel S., Tatsch K., Dahne I., Mager T., Scherer J., Hahn K. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. J. Nucl. Med. 39:1998;1138-1142.
40. 1 receptor blockade. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;423-429.
41. Farde L., Nordstrom A.L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatry Suppl. 17:1992;30-33.
42. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry. 45:1988;71-76.
43. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
44. Farde L., Nordstrom A.L., Nyberg S., Halldin C., Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J. Clin. Psychiatry. 55:1994;B67-B69. (Suppl.).
45. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Psychopharmacol. 15(Suppl. 1):1995;19S-23S.
46. Florijn W.J., Tarazi F.I., Creese I. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. J. Pharmacol. Exp. Ther. 280:1997;561-569.
47. Fu Y., Zhu Z.T., Chen L.J., Yu L.P., Jin G.Z. Behavioral characteristics of olanzapine: an atypical neuroleptic. Acta Pharmacol. Sin. 21:2000;329-334.
48. Fujiwara H. Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity, and brain dopamine metabolism in mice. Pharmacol. Biochem. Behav. 41:1992;301-308.
49. Gefvert O., Bergstrom M., Langstrom B., Lundberg T., Lindstrom L., Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 135:1998;119-126.
50. Gefvert O., Lundberg T., Wieselgren I.M., Bergstrom M., Langstrom B., Wiesel F., Lindstrom L. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. 11:2001;105-110.
51. Gessa G.L., Devoto P., Diana M., Flore G., Melis M., Pistis M. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex. Neuropsychopharmacology. 22:2000;642-649.
52. Goldstein J.M., Litwin L.C., Sutton E.B., Malick J.B. Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 249:1989;673-680.
53. Goldstein J.M., Litwin L.C., Sutton E.B., Malick J.B. Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology. 112:1993;293-298.
54. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 20:1997;31-37.
55. Grenhoff J., Ugedo L., Svensson T.H. Firing patterns of midbrain dopamine neurons: differences between A9 and A10 cells. Acta Physiol. Scand. 134:1988;127-132.
56. Grenhoff J., Tung C.S., Ugedo L., Svensson T.H. Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol. Toxicol. 66:1990;129-133. (Suppl.).
57. Gross H., Langner E. On the use of 7-chlor-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one in psychiatry. Arzneimittel-Forschung. 16:1966;1328-1330.
58. Groves P.M., Wilson C.J., Young S.J., Rebec G.V. Self-inhibition by dopaminergic neurons. Science. 190:1975;522-529.
59. Hand T.H., Hu X.T., Wang R.Y. Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res. 415:1987;257-269.
60. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science. 286:1999;105-107.
61. Hippius H. The history of clozapine. Psychopharmacology. 99:1989;S3-S5.
62. Hokfelt T., Ljungdahl A., Fuxe K., Johansson O. Dopamine nerve terminals in the rat limbic cortex: aspects of the dopamine hypothesis of schizophrenia. Science. 184:1974;177-1779.
63. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18:1966;925-964.
64. Huang N., Ase A.R., Hebert C., van Gelder N.M., Reader T.A. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem. Int. 30:1997;277-290.
65. Hyttel J. Effect of neuroleptics on the disappearance rate of [14C) labelled catecholamines formed from (14C)tyrosine in mouse brain. J. Pharm. Pharmacol. 26:1974;588-596.
66. Ichikawa J., Meltzer H.Y. The effect of chronic clozapine and haloperidol on basal dopamine release and metabolism in rat striatum and nucleus accumbens studied by in vivo microdialysis. Eur. J. Pharmacol. 176:1990;371-374.
67. Ichikawa J., Meltzer H.Y. Differential effects of repeated treatment with haloperidol and clozapine on dopamine release and metabolism in the striatum and the nucleus accumbens. J. Pharmacol. Exp. Ther. 256:1991;348-357.
68. Ichikawa J., Meltzer H.Y. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res. 574:1992;98-104.
69. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 907:2001;151-155.
70. Imperato A., Obinu M.C., Carta G., Mascia M.S., Casu M.A., Dazzi L., Gessa G.L. Neuroleptics cause stimulation of dopamine D1 receptors and their desensitization after chronic treatment. Eur. J. Pharmacol. 264:1994;55-60.
71. Janowsky A., Neve K.A., Kinzie J.M., Taylor B., de Paulis T., Belknap J.K. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. J. Pharmacol. Exp. Ther. 261:1992;1282-1290.
72. Jenner P., Hall M.D., Murugaiah K., Rupniak N., Theodorou A., Marsden C.D. Repeated administration of sulpiride for three weeks produces behavioural and biochemical evidence for cerebral dopamine receptor supersensitivity. Biochem. Pharmacol. 31:1982;325-328.
73. Jenner P., Rupniak N., Marsden C.D. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats. Psychopharmacology Suppl. 1985;2174-2181.
74. Kahn R.S., Davidson M. Serotonin, dopamine and their interactions in schizophrenia. Psychopharmacology. 112:1993;S1-S4.
75. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
76. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52:2001;503-517.
77. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57:1995;PL103-PL107.
78. Kapur S., Zipursky R., Remington G., Jones C., Makay G., Houle S. PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the treatment of schizophrenia. Am. J. Psychiatry. 154:1997;1525-1529.
79. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry. 155:1998;921-928.
80. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 157:2000;514-520.
81. Kasper S., Tauscher J., Kufferle B., Barnas C., Hesselmann B., Asenbaum S., Podreka I., Brucke T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. Psychopharmacology. 136:1998;367-373.
82. Kazawa T., Mikuni M., Higuchi T., Arai I., Takahashi K., Yamauchi T. Characterization of sulpiride-displaceable 3H-YM-09151-2 binding sites in rat frontal cortex and the effects of subchronic treatment with haloperidol on cortical D-2 dopamine receptors. Life Sci. 47:1990;531-537.
83. Kehr W., Carlsson A., Lindqvist M., Magnusson T., Atack C. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol. 24:1972;744-747.
84. Kelland M.D., Chiodo L.A., Freeman A.S. Anesthetic influences on the basal activity and pharmacological responsiveness of nigrostriatal dopamine neurons. Synapse. 6:1990;207-209.
85. Knable M.B., Heinz A., Raedler T., Weinberger D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. 75:1997;91-101.
86. Kohler C., Ogren S.O., Haglund L., Angeby T. Regional displacement by sulpiride of [3H]spiperone binding in vivo. Biochemical and behavioural evidence for a preferential action of limbic and nigral dopamine receptors. Neurosci. Lett. 13:1979;51-56.
87. Kolenik S.A. III, Hoffman F.J., Bowers M.B. Sensitivity of regional brain dopamine systems to haloperidol. Biol. Psychiatry. 25:1989;815-817.
88. Kufferle B., Tauscher J., Asenbaum S., Vesely C., Podreka I., Brucke T., Kasper S. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology. 133:1997;323-328.
89. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
90. Kusumi I., Ishikane T., Matsubara S., Koyama T. Long-term treatment with haloperidol or clozapine does not affect dopamine D4 receptors in rat frontal cortex. J. Neural Transm. Gen. Sect. 101:1995;231-235.
91. Laduron P., de Bie K., Leysen J. Specific effect of haloperidol on dopamine turnover in the frontal cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 296:1977;183-185.
92. Laverty R., Sharman D.F. Modification by drugs of the metabolism of 3,4-dihydroxyphenylethylamine, noradrenaline and 5-hydroxytryptamine in the brain. Brit. J. Pharmacol. 24:1965;759-772.
93. Lerner P., Nose P., Gordon E.K., Lovenberg W. Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover. Science. 197:1977;181-183.
94. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology. 112:1993;S40-S54.
95. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry. 55:1994;5-12.
96. Magnusson O., Fowler C.J., Kohler C., Ogren S.O. Dopamine D2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology. 25:1986;187-197.
97. Marcus M.M., Nomikos G.G., Svensson T.H. Differential actions of typical and atypical antipsychotic drugs on dopamine release in the core and shell of the nucleus accumbens. Eur. Neuropsychopharmacol. 6:1996;29-38.
98. Matsumoto T., Uchimura H., Hirano M., Kim J.S., Yokoo H., Shimomura M., Nakahara T., Inoue K., Oomagari K. Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete dopaminergic areas of rat brain. Eur. J. Pharmacol. 89:1983;27-33.
99. Mefford I.N., Roth K.A., Agren H., Barchas J.D. Enhancement of dopamine metabolism in rat brain frontal cortex: a common effect of chronically administered antipsychotic drugs. Brain Res. 475:1988;380-384.
100. Meller E., Bohmaker K., Rosengarten H., Friedhoff A.J. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex. Res. Commun. Chem. Pathol. Pharmacol. 37:1982;323-332.
101. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
102. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr. Bull. 17:1991;263-287.
103. Memo M., Battaini F., Spano P.F., Trabucchi M. Sulpiride and the role of dopaminergic receptor blockade in the antipsychotic activity of neuroleptics. Acta Psychiatr. Scand. 63:1981;314-324.
104. Mereu G., Casu M., Gessa G.L. (-)-Sulpiride activates the firing rate and tyrosine hydroxylase activity of dopaminergic neurons in unanesthetized rats. Brain Res. 264:1983;105-110.
105. Mereu G., Lilliu V., Vargiu P., Muntoni A.L., Diana M., Gessa G.L. Failure of chronic haloperidol to induce depolarization inactivation of dopamine neurons in unanesthetized rats. Eur. J. Pharmacol. 264:1994;449-453.
106. Millan M.J., Gobert A., Newman-Tancredi A., Audinot V., Lejeune F., Rivet J.M., Cussac D., Nicolas J.P., Muller O., Lavielle G. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J. Pharmacol. Exp. Ther. 286:1998;1341-1355.
107. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
108. Moleman P., Bruinvels J., Van Valkenburg C.F. Haloperidol inhibits the disappearance of acidic dopamine metabolites from rat striatum. J. Pharm. Pharmacol. 30:1978;583-585.
109. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., Mantil J. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology. 25:2001;476-488.
110. Nishibe Y., Matsuo Y., Yoshizaki T., Eigyo M., Shiomi T., Hirose K. Differential effects of sulpiride and metoclopramide on brain. Homovanillic acid levels and shuttle box avoidance after systemic and intracerebral administration. Naunyn-Schmiedeberg's Arch. Pharmacol. 321:1982;190-194.
111. Nomikos G.G., Iurlo M., Andersson J.L., Kimura K., Svensson T.H. Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology. 115:1994;147-156.
112. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., Uppfeldt G. Nordstrom Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry. 33:1993;227-235.
113. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry. 152:1995;1444-1449.
114. Nyback H., Borzecki Z., Sedvall G. Accumulation and disappearance of catecholamines formed from tyrosine-14C in mouse brain; effect of some psychotropic drugs. Eur. J. Pharmacol. 4:1968;395-403.
115. Nyberg S., Farde L., Eriksson L., Halldin C., Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 110:1993;265-272.
116. Nyberg S., Farde L., Halldin C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
117. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry. 156:1999;869-875.
118. Ogren S.O., Hall H., Kohler C., Magnusson O., Lindbom L.O., Angeby K., Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur. J. Pharmacol. 20(102):1984;459-474.
119. O'Keeffe R., Sharman D.F., Vogt M. Effect of drugs used in psychoses on cerebral dopamine metabolism. Br. J. Pharmacol. 38:1970;287-304.
120. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Kumagai T., Nakazato A., Nagamine M., Yamaguchi K., Tomisawa K. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats. Br. J. Pharmacol. 121:1997;515-525.
121. Pehek E.A., Yamamoto B.K. Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63:1994;2118-2124.
122. Pehek E.A., Meltzer H.Y., Yamamoto B.K. The atypical antipsychotic drug amperozide enhances rat cortical and striatal dopamine efflux. Eur. J. Pharmacol. 240:1993;107-109.
123. 3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 280:1997;73-82.
124. Peuskens J., Bech P., Moller H.J., Bale R., Fleurot O., Rein W. Amisulpride vs. rispiridone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 88:1999;107-117.
125. Pilowsky L.S., Busatto G.F., Taylor M., Costa D.C., Sharma T., Sigmundsson T., Ell P.J., Nohria V., Kerwin R.W. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology. 124:1996;148-153.
126. Prosser E.S., Pruthi R., Csernansky J.G. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology. 99:1989;109-116.
127. Rollema H., Westerink B.H.C., Grol C.J. Correlation between neuroleptic-induced suppression of stereotyped behaviour and HVA concentrations in rat brain. J. Pharm. Pharmacol. 28:1976;321-323.
128. Rollema H., Lu Y., Schmidt A.W., Zorn S. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol. 338:1997;R3-R5.
129. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry. 48:2000;229-237.
130. Roos B.E. Effect of tranquillizers on the level of homovanillic acid in the corpus striatum. J. Pharm. Pharmacol. 17:1965;820-821.
131. Rupniak N.M., Kilpatrick G., Hall M.D., Jenner P., Marsden C.D. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats. Psychopharmacology. 84:1984;512-519.
132. Rupniak N.M., Hall M.D., Mann S., Fleminger S., Kilpatrick G., Jenner P., Marsden C.D. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem. Pharmacol. 34:1985;2755-2763.
133. Rupniak N.M., Hall M.D., Kelly E., Fleminger S., Kilpatrick G., Jenner P., Marsden C.D. Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs. J. Neural Transm. 62:1985;249-266.
134. Saller C.F., Kreamer L.D., Adamovage L.A., Salama A.I. Dopamine receptor occupancy in vivo: measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Life Sci. 45:1989;917-929.
135. Saller C.F., Czupryna M.J., Salama A.I. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. J. Pharmacol. Exp. Ther. 253:1990;1162-1170.
136. Sayers A.C., Burki H.R., Ruch W., Asper H. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia. 41:1975;97-104.
137. Scatton B. Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration. Eur. J. Pharmacol. 46:1977;363-369.
138. Scatton B., Bischoff S., Dedek J., Korf J. Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity. Eur. J. Pharmacol. 44:1977;287-292.
139. Scherer J., Tatsch K., Schwarz J., Oertel W.H., Konjarczyk M., Albus M. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr. Scand. 90:1994;266-268.
140. Schoemaker H., Claustre Y., Fage D., Rouquier L., Chergui K., Curet O., Oblin A., Gonon F., Carter C., Benavides J., Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 280:1997;83-97.
141. Schotte A., Janssen P.F., Megens A.A., Leysen J.E. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Res. 631:1993;191-202.
142. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
143. See R.E., Toga A.W., Ellison G. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. Neural Transm. Gen. Sect. 82:1990;93-109.
144. See R.E., Lynch A.M., Aravagiri M., Nemeroff C.B., Owens M.J. Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. Brain Res. 704:1995;202-209.
145. Seeger T.F., Thal L., Gardner E.L. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol. Psychopharmacology. 76:1982;182-187.
146. Seeman P., Ulpian C. Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur. J. Pharmacol. 94:1983;145-148.
147. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
148. Severson J.A., Robinson H.E., Simpson G.M. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug. Psychopharmacology. 84:1984;115-119.
149. Skarsfeldt T. Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in rats. Life Sci. 42:1988;1037-1044.
150. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse. 10:1992;25-33.
151. Skarsfeldt T. Comparison of short-term administration of sertindole, clozapine and haloperidol on the inactivation of midbrain dopamine neurons in the rat. Eur. J. Pharmacol. 254:1994;291-294.
152. Skarsfeldt T., Perregaard J. Sertindole, a new neurolepic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur. J. Pharmacol. 182:1990;613-614.
153. Stanley M., Wilk S. Acute and chronic effects of haloperidol and clozapine on dopamine metabolism in two dopamine rich areas of the rat brain. Res. Commm. Psychol. Psych. Behav. 5:1980;37-47.
154. Sorensen S.M., Kehne J.H., Fadayel G.M., Humphreys T.M., Ketteler H.J., Sullivan C.K., Taylor V.L., Schmidt C.J. Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266:1993;684-691.
155. Stawarz R.J., Hill H., Robinson S.E., Setler P., Dingell J.V., Sulser F. On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain. Psychopharmacologia. 43:1975;125-130.
156. Stockmeier C.A., DiCarlo J.J., Zhang Y., Thompson P., Meltzer H.Y. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J. Pharmacol. Exp. Ther. 266:1993;1374-1384.
157. Svartengren J., Celander M. The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding. Eur. J. Pharmacol. 254:1994;73-81.
158. Tagliamonte A., DeMontis G., Olianas M., Vargiu L., Corsini G.U., Gessa G.L. Selective increase of brain dopamine synthesis by sulpiride. J. Neurochem. 24:1975;707-710.
159. Talmaciu R.K., Hoffmann I.S., Cubeddu L.X. Dopamine autoreceptors modulate dopamine release from the prefrontal cortex. J. Neurochem. 47:1986;865-870.
160. Talvik M., Nordstrom A.L., Nyberg S., Olsson H., Halldin C., Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am. J. Psychiatry. 158:2001;926-930.
161. Tarazi F.I., Florijn W.J., Creese I. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience. 78:1997;985-996.
162. Tauscher J., Kufferle B., Asenbaum S., Fischer P., Pezawas L., Barnas C., Tauscher-Wisniewski S., Brucke T., Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 141:1999;175-181.
163. Thierry A.M., Stinus L., Blanc G., Glowinski J. Some evidence for the existence of dopaminergic neurons in the rat cortex. Brain Res. 50:1973;230-234.
164. Todorova A., Dimpfel W. Multiunit activity from the A9 and A10 areas in rats following chronic treatment with different neuroleptic drugs. Eur. Neuropsychopharmacol. 4:1994;491-501.
165. Trichard C., Paillere-Martinot M.L., Attar Levy D., Recassens C., Monnet F., Martinot J.L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry. 155:1998;505-508.
166. Vanhauwe J.F., Ercken M., van de Wiel D., Jurzak M., Leysen J.E. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells. Psychopharmacology. 150:2000;383-390.
167. Van Rossum J.M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Ther. 160:1966;492-494.
168. Volonte M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
169. Von Stralendorff B., Ackenheil M., Zimmermann J. Acute and chronic effects of carpipramine, clozapine, haloperidol and sulpiride on the metabolism of biogenic amines in the rat brain. Arzneimittel-Forschung. 26:1976;1096-1098.
170. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. Suppl. 367:1971;1-48.
171. Waldmeier P.C., Maitre L. On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs. J. Neurochem. 27:1976;589-597.
172. Waldmeier P.C., Maitre L. Clozapine: reduction of the initial dopamine turnover increase by repeated treatment. Eur. J. Pharmacol. 38:1976;197-203.
173. Walters J.R., Roth R.H. Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 296:1976;5-14.
174. Wan D.C., Dean B., Pavey G., Copolov D.L. Treatment with haloperidol or clozapine causes changes in dopamine receptors but not adenylate cyclase or protein kinase C in the rat forebrain. Life Sci. 59:1996;2001-2008.
175. Westerink B.H.C., Korf J. Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain. Eur. J. Pharmacol. 33:1975;31-40.
176. Westerink B.H.C., Korf J. Regional brain levels of DOPAC and HVA: concurrent fluorometric measurement and influence of drugs. Eur. J. Pharmacol. 38:1976;281-291.
177. Westerink B.H.C., Korf J. Acidic dopamine metabolites in cortical areas of the rat brain: localization and effects of drugs. Brain Res. 113:1976;429-434.
178. Westerink B.H.C., De Vries J.B. On the mechanism of neuroleptic induced increase in striatal dopamine release: brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals. Neurosci. Lett. 99:1989;197-202.
179. Westerink B.H., Kikkert R.J. Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J. Neurochem. 46:1986;1145-1152.
180. Westerink B.H.C., Lejeune B., Korf J., Van Praag H.M. On the significance of regional dopamine metabolism in the rat brain for the classification of centrally acting drugs. Eur. J. Pharmacol. 42:1977;179-190.
181. Westerink B.H.C., Enrico P., Feimann J., de Vries J.B. The pharmacology of mesocortical dopaminergic neurons: a dual-probe microdialysis study in the ventral tegmental area and prefrontal cortex of the rat brain. J. Pharmacol. Exp. Ther. 285:1998;143-154.
182. Westerink B.H.C., Kawahara Y., de Boer P., Geels C., de Vries J.B., van Vliet H.B., Wikstrom H.V., van Kalkeren A., van Vloet B., Kruse C.G., Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412:2001;127-138.
183. White F.J., Wang R.Y. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 221:1983;1054-1057.
184. White F.J., Wang R.Y. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci. 32:1983;983-993.
185. White F.J., Wang R.Y. A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity to dopamine agonists. Life Sci. 34:1984;1161-1170.
186. White F.J., Wang R.Y. Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: microiontophoretic studies. J. Pharmacol. Exp. Ther. 231:1984;275-280.
187. Wiesel F.A., Sedvall G. Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat. Eur. J. Pharmacol. 30:1975;364-367.
188. Wiesel F.A., Farde L., Nordstrom A.L., Sedvall G. Central D1- and D2-receptor occupancy during antipsychotic drug treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 14:1990;759-767.
189. Wilk S., Glick S.D. Dopamine metabolism in the nucleus accumbens: the effect of clozapine. Eur. J. Pharmacol. 37:1976;203-206.
190. Wilk S., Watson E., Stanley M.E. Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and to clozapine. J. Pharmacol. Exp. Ther. 195:1975;265-270.
191. Xiberas X., Martinot J.L., Mallet L., Artiges E., Canal M., Loc'h C., Maziere B., Paillere-Martinot M.L. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J. Clin. Psychopharmacol. 21:2001;207-214.
192. Yamamoto B.K., Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14:1994;4159-4166.